Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

afsha - GI > obesity > Flashcards

obesity Flashcards

1
Q

name some conditions that obesity increases the risk of developing

A
  • T2D
  • hypertension
  • CVD
  • dyslipidaemia
  • fatty liver disease
  • gallstones
  • some types of cancer
  • reproductive problems
  • respitatory and MSK conditions
  • GORD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

BMI is a measure of ..

A

obesity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Waist to height ratio is a measure of …

A

central adiposity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Why should BMI alone be interpreted with caution , and in which individuals in particular

A

not a direct measure of central adiposity, esp in people who are very muscular or have muscle weakness or atrophy, and in those 65 and over

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

In patients with BMI below 35 including in the healthy range, what else should be measured

A

waist to height ratio

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

define healthy, overweight and obese in patients from a white background (BMI scale)

A

Healthy 18.5-24.9
Overweight 25-29.9
Obesity class 1 30-34.9
Obesity class 2 35-39.9
Obesity class 3 40 or more

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

BA, AC, SA, Chinese, other Asian, or ME family background - these pt are at increased risk of chronic health conditions at lower BMI thresholds.
Overweight or obese in these individuals is defined as:

A

Overweight 23-27.4
Obesity 27.5 or above
Class 2 and 3 are usually identified by reducing the thresholds above 2.5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

In all individuals with a BMI <35, central adiposity based on waist to height ratio is defined as

A
  • Increased central adiposity: W-t-H ratio 0.5-0.9
    • High central adiposity: W-t-H ratio 0.6 or more
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

true or false - Individuals with a BMI of 35 or more are at v high risk of obesity related-health problems, regardless of W-t-H ratio

A

true

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

name one potential underlying cause of overweight

A

hypothyroidism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

name some medications that are known to cause weight gain

A

atypical antipsychotics
beta blockers
insulin when used for T2D
lithium
SV
SUs
thiazolidinediones
TCAs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

true or false - you can use drug treatment as the sole element of treatment of obesity in some patients

A

false
NEVER use as the sole element of treatment
Must be used as part of an overall weight management plan

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

When can you consider orlistat

A

BMI ≥ 30 kg/m2 in whom diet, exercise and behavioural changes failed to achieve an adequate reduction in weight, or in pt with BMI ≥28 in the presence of associated risk factors e.g. diabetes, high cholesterol, hypertension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

These two drugs can be considered for certain patients under specialist care only

(hint GLP1 agon)

A

liraglutide OD, semaglutide once weekly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

true or false - drug treatment may be used to maintain weight loss rather than to continue to lose weight

A

true

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

true or false - wright loss may be slower in pt with T2D

A

true

17
Q

who can you consider treatment with SETMELANOTIDE in

A

expert supervision in pt with specific genetic conditions

18
Q

what does satiety mean

A

feeling of being full

19
Q

name some drugs that produce a feeling of satiety which have been used (unlicensed) in an attempt to control appetite, but there is little evidence for their efficacy

hint - bulk forming

A
  • methylcellulose
  • sterculia
20
Q

when can you consider bariatric surgery for pt

A

BMI ≥ 40 kg/m2, or between 35-39.9 and a significant disease (e.g. CVD, NAFLD, obstructive sleep apnea, T2D, hypertension) which could be improved with weight loss
may also be considered for patients with a BMI of 30 to 34.9 who have recent onset T2D

21
Q

orlistat MOA

A

lipase inhibitor, reduces the absorption of dietary fat.

22
Q

dose of orlistat & how long to continue it for

A

120mg up to TDS, dose to be taken immediately before, or during, or up to 1 hour after each pain meal

continue treatment beyond 12 weeks only if weight loss since start of treatment exceeds 5% (target for initial weight loss may be lower in pt with T2D)

23
Q

If a meal if missed or contains no fat, should you still take dose of orlistat

A

No, miss dose

24
Q

2 contraindications for orlistat

A

cholestasis
chronic malabsorption syndrome

25
Q

Can orlistat affect absorption of vitamins?

A

Yes it can impair absorption of fat soluble vitamins
Vitamin supplementation (especially of vitamin D) may be considered if there is concern about deficiency of fat-soluble vitamins.

26
Q

4 SE of orlistat

A

abdominal pain - can reduce by reducing fat intake
anxiety
diarrhoea
GI disorders

27
Q

What is the brand name for OTC orlistat and what strength is it

A

Alli 60mg

28
Q

What should a persons diet be like if they are on orlistat

A

nutritionally balanced, mildly hypocaloric diet that contains approximately 30 % of calories from fat. It is recommended that the diet should be rich in fruit and vegetables. The daily intake of fat, carbohydrate and protein should be distributed over three main meals.

29
Q

MOA setmetalonide

A

centrally-acting selective melanocortin-4 receptor agonist that regulates hunger, satiety, and energy expenditure, thereby promoting weight loss.

30
Q

Indication & route - setmelanotide

A

Obesity with underlying genetic aetiology (under expert supervision)

Via SC injection

31
Q

Orlistat indication

A

Adjunct in obesity (in conjunction with a mildly hypocaloric diet in individuals with a body mass index (BMI) of 30 kg/m2 or more or in individuals with a BMI of 28 kg/m2 or more in the presence of other risk factors such as type 2 diabetes, hypertension, or hypercholesterolaemia)
for orlistat

32
Q

Naltrexone & bupropion indication

A

Adjunct in obesity (in conjunction with dietary measures and increased physical activity in individuals with a body mass index (BMI) of 30 kg/m2 or more or in individuals with a BMI of 27 kg/m2 or more in the presence of one or more weight related co-morbidity)

33
Q

MHRA advice - naltrexone/bupropion - risk of adverse reactions that could affect ability to drive

A
  • commonly associated with dizziness or somnolence
  • rarely with loss of consciousness or seizure
34
Q

Naltrexone/bupropion is contraindicated in

A

uncontrolled hypertension

35
Q

Alli OTC or POM orlistat - can it be used in children

A

no adults only

36
Q

dose of Alli 60mg (OTC orlistat) and how long to continue treatment for

A

60mg TDS

max 180mg in 24hours

treatment should not exceed 6 months.

if unable to lose weight after 12 weeks, see GP or pharmacist; may need to discontinue treatment

37
Q

when taking orlistat, pt should be on nutritionally balanced, mildly hypocaloric diet that contains approximately …..% of calories from fat

A

30%

38
Q

treatment with orlistat may potentially impair the absorption of fat soluble vitamins

name the 4 fat soluble vits

A

a, d, e, k

afsha - GI (31 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions